KR101519840B1 - Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도 - Google Patents

Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도 Download PDF

Info

Publication number
KR101519840B1
KR101519840B1 KR1020107011743A KR20107011743A KR101519840B1 KR 101519840 B1 KR101519840 B1 KR 101519840B1 KR 1020107011743 A KR1020107011743 A KR 1020107011743A KR 20107011743 A KR20107011743 A KR 20107011743A KR 101519840 B1 KR101519840 B1 KR 101519840B1
Authority
KR
South Korea
Prior art keywords
ser
leu
ile
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107011743A
Other languages
English (en)
Korean (ko)
Other versions
KR20100087346A (ko
Inventor
데이비드 레이트
Original Assignee
아피토프 인터내셔날 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아피토프 인터내셔날 엔브이 filed Critical 아피토프 인터내셔날 엔브이
Publication of KR20100087346A publication Critical patent/KR20100087346A/ko
Application granted granted Critical
Publication of KR101519840B1 publication Critical patent/KR101519840B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107011743A 2007-12-04 2008-12-03 Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도 Expired - Fee Related KR101519840B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723712.6 2007-12-04
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Publications (2)

Publication Number Publication Date
KR20100087346A KR20100087346A (ko) 2010-08-04
KR101519840B1 true KR101519840B1 (ko) 2015-05-18

Family

ID=38982965

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107011743A Expired - Fee Related KR101519840B1 (ko) 2007-12-04 2008-12-03 Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도

Country Status (25)

Country Link
US (1) US8445448B2 (enExample)
EP (1) EP2227488B3 (enExample)
JP (2) JP5501245B2 (enExample)
KR (1) KR101519840B1 (enExample)
CN (2) CN103709234B (enExample)
AU (1) AU2008332968B2 (enExample)
BR (1) BRPI0820143A2 (enExample)
CA (2) CA3005013C (enExample)
CY (1) CY1115168T1 (enExample)
DK (1) DK2227488T6 (enExample)
EA (1) EA019370B1 (enExample)
EC (1) ECSP10010327A (enExample)
ES (1) ES2458315T7 (enExample)
GB (1) GB0723712D0 (enExample)
HR (1) HRP20140344T4 (enExample)
IL (1) IL205780A (enExample)
MX (1) MX2010006084A (enExample)
MY (1) MY150995A (enExample)
NZ (1) NZ585217A (enExample)
PL (1) PL2227488T6 (enExample)
PT (1) PT2227488E (enExample)
SI (1) SI2227488T1 (enExample)
UA (1) UA101003C2 (enExample)
WO (1) WO2009071886A1 (enExample)
ZA (1) ZA201002997B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
SI2300497T1 (sl) * 2008-06-24 2013-02-28 Octapharma Ag Postopek za äťiĺˇäťenje koagulacijskega faktorja viii
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
US20120135917A1 (en) * 2009-06-16 2012-05-31 Eisaku Yoshihara Anti-Gram Negative Bacteria Agent
DK2632479T3 (en) * 2010-10-27 2017-08-07 Baxalta GmbH FVIII PEPTIDES FOR IMMUNT TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS
PL3453402T3 (pl) 2012-01-12 2022-03-21 Bioverativ Therapeutics Inc. Zmniejszenie immunogenności przeciwko czynnikowi viii u osób poddawanych terapii czynnikiem viii
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
WO2017096329A1 (en) 2015-12-03 2017-06-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070389A (ko) * 1997-01-22 2000-11-25 파라비 레이 응고 및 종양 치료용 조직 인자 방법 및 조성물
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
KR20070016119A (ko) * 2004-02-09 2007-02-07 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT94427A (pt) 1989-06-20 1991-03-20 Scripps Clinic Res Processo para a preparacao de polipeptidos que inibem a ligacao de factor viii humano a fosfolipidos
SI1311542T1 (sl) * 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070389A (ko) * 1997-01-22 2000-11-25 파라비 레이 응고 및 종양 치료용 조직 인자 방법 및 조성물
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia
WO2002060917A3 (en) 2000-12-01 2003-01-30 Univ Minnesota Method to treat hemophilia
KR20070016119A (ko) * 2004-02-09 2007-02-07 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질

Also Published As

Publication number Publication date
CN103709234A (zh) 2014-04-09
EP2227488A1 (en) 2010-09-15
DK2227488T3 (da) 2014-04-22
PL2227488T6 (pl) 2015-04-30
HRP20140344T1 (en) 2014-05-09
ES2458315T7 (es) 2015-02-18
EA019370B1 (ru) 2014-03-31
HK1144292A1 (en) 2011-02-11
AU2008332968B2 (en) 2014-03-20
ES2458315T3 (es) 2014-04-30
PT2227488E (pt) 2014-04-21
MX2010006084A (es) 2010-06-23
CA3005013C (en) 2021-11-16
DK2227488T6 (en) 2015-02-16
US20100323966A1 (en) 2010-12-23
WO2009071886A1 (en) 2009-06-11
CN101889024A (zh) 2010-11-17
AU2008332968A1 (en) 2009-06-11
EP2227488B1 (en) 2014-01-22
GB0723712D0 (en) 2008-01-16
US8445448B2 (en) 2013-05-21
JP6063402B2 (ja) 2017-01-18
JP5501245B2 (ja) 2014-05-21
CN103709234B (zh) 2017-01-18
HRP20140344T4 (hr) 2015-07-31
UA101003C2 (uk) 2013-02-25
EP2227488B3 (en) 2014-11-19
CY1115168T1 (el) 2016-12-14
ZA201002997B (en) 2011-07-27
BRPI0820143A2 (pt) 2015-05-12
KR20100087346A (ko) 2010-08-04
CA3005013A1 (en) 2009-06-11
CA2707559C (en) 2018-07-03
IL205780A0 (en) 2010-11-30
NZ585217A (en) 2012-11-30
MY150995A (en) 2014-03-31
PL2227488T3 (pl) 2014-07-31
IL205780A (en) 2015-06-30
CN101889024B (zh) 2014-04-23
JP2011505414A (ja) 2011-02-24
CA2707559A1 (en) 2009-06-11
JP2014088440A (ja) 2014-05-15
SI2227488T1 (sl) 2014-06-30
EA201070681A1 (ru) 2010-10-29
ECSP10010327A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
KR101519840B1 (ko) Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도
KR101673889B1 (ko) Ｆⅷ-유래 펩타이드
KR102165486B1 (ko) 펩타이드
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180417

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190508

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190508